Skip to main content

News & Events

News & Announcements

New Biomere Executive

BRM/Biomere Appoints Alain Stricker-Krongrad, Ph.D., as Senior Vice President of Science and Business Development

Stricker-Krongrad to Guide Company’s Research Efforts from Baltimore Laboratory Facilities

WORCESTER, MA./BALTIMORE, MD., January 24, 2010 -- Biomedical Research Models Inc./Biomere, a privately held preclinical contract research organization (CRO) that specializes in life-threatening disease areas such as autoimmune, multiple sclerosis, diabetes and virology, announced today the appointment of Alain Stricker-Krongrad, Ph.D. as Senior Vice President of Science and Business Development. In his new Baltimore-based position, Dr. Stricker-Krongrad will oversee governmental and contractual preclinical research and guide BRM/Biomere during the national expansion phase of its business.
“Biomedical Research Models/Biomere is very fortunate to have attracted a true leader in preclinical outsourcing and development fields to guide its ambitious research efforts. We welcome Dr. Stricker-Krongrad to our team,” said President Dennis Guberski.

With more than 20 years of experience in pharmacology and preclinical research, Dr. Stricker-Krongrad joins Biomedical Research Models Inc. at its laboratory facilities within the University of Maryland BioPark in Baltimore, Maryland. Most recently, Dr. Stricker-Krongard served as Chief Scientific Officer of Charles River Laboratories (CRL) where he helped advance key science-based programs and foster science-related initiatives and capabilities. From 2006 to 2008, Dr. Stricker-Krongrad was the director and head of preclinical safety and pharmacology at CRL, Preclinical Services. During his tenure he developed short- and long-term strategic plans for new technologies and services and was in charge of the non-clinical evaluation (efficacy and safety) of synthetics, biologics, cell-based products, devices and surgical products. Dr. Stricker-Krongrad also held managerial positions at Millennium Pharmaceuticals and Athersys in the United States and at Novartis in Switzerland. Dr. Stricker-Krongrad obtained his Ph.D. in Pharmacology at the University of Henri Poincare (France). He conducted his post-doctoral training at INSERM, where he received two international awards for his research, and his post-graduate training in Clinical Pharmacology, Drug Development and Regulation at Tufts University. He has published more than 60 peer-reviewed papers and is a member of the Editorial Board of Expert Opinion in Drug Discovery.

“We are extremely pleased to have Dr. Stricker-Krongrad among the business and scientific leadership housed within the BioPark,” said Jim Hughes President, University of Maryland Baltimore Research Park Corporation. “BRM/Biomere is an important tenant within the BioPark, and Dr. Stricker-Krongrad is a welcome addition to our rich community of life science leaders.”

About BRM/Biomere

The USPHS-NIH-NIDDK has chosen BRM/Biomere as their designated testing center for the Type1 Diabetes Preclinial Testing Program Rapid Access to Intervention Development (T1D PTP RAID) program. Since 1977 our scientists have developed and maintained proprietary disease models. We are also a reliable choice for colony management for transgenic murine models. The company offers detailed genetic database management, quarantine housing, phenotyping, PCR genotyping, and rederivation (cesarean, embryo transfer).Our AAALAC accredited facilities in MD offer containment as well as pathogen free barrier housing which accommodates bio-containment levels for diverse areas of research. In summary, our experienced staff, proprietary animal models, colony management, and facilities provide a cost effective solution for companies requiring reliable preclinical testing services.

For more information, please visit us at www.biomere.com